Diabetes drug may shield kidneys from chemo damage
NCT ID NCT07018622
Summary
This study is testing whether a diabetes medication called dapagliflozin can protect the kidneys from damage caused by platinum-based chemotherapy. Researchers will give the drug or a placebo to 46 adults with solid tumors before and during their chemo. They will measure specific markers in the urine to see if the drug reduces signs of kidney injury, which could help patients complete their cancer treatment without harmful delays.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
RECRUITINGMéxico, Tlalpan, 14080, Mexico
Conditions
Explore the condition pages connected to this study.